We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PTC

News List

Aurobindo inks pact with Advent Pharmaceuticals for $12.5 million biospectrumasia
November 14, 2018
To acquire Australian pharma firm’s product
M&As this week: PTC Therapeutics, Cambrex pharmaceutical-technology
July 30, 2018
PTC Therapeutics has signed an agreement to acquire Agilis Biotherapeutics for $945m.
PTC inks $200M Agilis takeover to snag late-phase gene therapy fiercebiotech
July 26, 2018
PTC Therapeutics is paying $200 million upfront to acquire Agilis Biotherapeutics. The deal gives PTC ownership of a gene therapy treatment for rare neurotransmitter disease AADC deficiency that is set to go before the FDA next year.
PTC Therapeutics’ results in SMA has Biogen nervous pharmafile
June 22, 2018
Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that treatment is pretty central to the biotech’s portfolio, bringing in $364 million in revenue in the first quarter.

Previous page 1 2 Next page